Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

15.36 -0.66 (-4.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 320,210
Open 15.95
Bid (Size) 15.32 (4)
Ask (Size) 15.35 (1)
Prev. Close 16.02
Today's Range 15.21 - 16.13
52wk Range 5.810 - 16.33
Shares Outstanding 23,914,879
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
From Alpine Immune Sciences, Inc.
Via Business Wire
The Latest Analyst Ratings for Alpine Immune Sciences
Via Benzinga

Performance

YTD
+106.73%
+106.73%
1 Month
+8.70%
+8.70%
3 Month
+20.75%
+20.75%
6 Month
+40.92%
+40.92%
1 Year
+127.89%
+127.89%

More News

Read More
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
What 8 Analyst Ratings Have To Say About Alpine Immune Sciences
Via Benzinga
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Proposed Public Offering
From Alpine Immune Sciences, Inc.
Via Business Wire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Apple, Coinbase Global, Fortinet And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Is Alpine Immune Sciences Stock Trading Higher Today?
Via Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2023
Via Benzinga
Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
From Alpine Immune Sciences, Inc.
Via Business Wire
IgAN Treatment Market Worth Over $6B By 2032: Analyst Bearish On Povetacicept's Promising Role
Via Benzinga
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
From Alpine Immune Sciences, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Via Benzinga
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.